Alector (NASDAQ: ALEC)
Alector Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Alector Company Info
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.
News & Analysis
Why Alector Shares Are Diving Today
There has been a major shakeup in the C-suite.
Why Alector Zoomed 12% Higher Today
The company has yet another fine July trading day thanks to a Citigroup analyst.
Why Alector Blasted Higher Today
It's not every day that a small biotech announces a major collaboration deal with a deep-pocketed pharmaceutical giant.
Don't Miss What Sent These 2 Little-Known Nasdaq Newsmakers Soaring
One of these companies is making big waves.
Why Alector Is Tumbling 28.7% Today
Investors appear nervous that COVID-19 precautions could create obstacles to trials evaluating its lead drug candidate.
What Company Will Eli Lilly Buy Next?
Following the announced buyout of Dermira, Eli Lilly’s management said more acquisitions are in store for 2020.
Biotech’s Year-End To-Do List
The remaining weeks of December are chock-full of clinical trial results and FDA approval decisions that savvy investors can take advantage of.
2 Biotech Stocks Fighting Alzheimer’s Disease to Own Now
No new drugs have been approved for Alzheimer’s disease since 2003. However, new approaches may soon bring options for the 5.7 million Americans suffering from the disease.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.